GlassScriptPhysician profile
Ann K Gerald
NPI 1760431050
$4,667.81
in general payments reported to CMS, 2019-2025
25 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $264 · 2021: $757 · 2022: $1,003 · 2023: $929 · 2024: $898 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.75 | 2019-2025 | |
| Allergan, INC. | $378.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $350.90 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $297.28 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $267.57 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $250.45 | 2019-2025 | Adbry |
| Genzyme Corporation | $243.76 | 2020-2024 | |
| Janssen Biotech, INC. | $169.03 | 2019-2025 | Tremfya, Simponi, Remicade |
| Regeneron Healthcare Solutions, INC. | $150.09 | 2022-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.57 | 2019-2024 | Cabtreo |
| Pfizer INC. | $128.87 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $122.17 | 2019 | |
| Incyte Corporation | $99.94 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $91.06 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $73.57 | 2020-2025 | Aklief, Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $68.54 | 2019-2021 | |
| Amgen INC. | $62.70 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $51.94 | 2021-2023 | Cimzia |
| Epi Health, LLC | $39.75 | 2021-2022 | |
| Dermira, INC. | $39.44 | 2019-2020 | |
| Lilly USA, LLC | $15.65 | 2022 | |
| Nabriva Therapeutics, Plc | $13.99 | 2021 | |
| Vyne Pharmaceuticals INC. | $13.97 | 2021 | |
| Almirall LLC | $13.48 | 2019 | |
| Therapeuticsmd, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Gerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.